Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.05

-0.6%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (23713)	5/21/2007 9:43:47 PM
From: Proud Deplorable	Read Replies (1) of 52153

Permit me I have a bit of knowledge of these 2 drugs.....Actos and Avandia are NOT safe to use. Further information is available in the book Worst Pils/Best Pills by Public Citizen which is THE Bible of Prescription Drugs and everyone who considers taking any prescription drug should own a copy no matter what! Actos and Avandia have a DO NOT USE flag on them. These drugs are too much like Rezulin which was banned for causing deaths and other lesser damage ;-) like liver toxicity etc. ------------------------------ DIABETES DRUG BANNED IN THE UK © What Doctors Don't Tell You (Volume 8, Issue 11) -------------------------------------------------------------------------------- A new drug for diabetes, troglitazone (Romozin), has been declared unsafe and banned in Britain. The decision has come after six people died and numerous liver injury cases were reported worldwide. Over 150 people have suffered reactions from troglitazone, out of the three hundred thousand patients worldwide who have been treated with the drug since its launch in October 1997. Reactions to the drug have ranged from severe liver damage to liver necrosis (cell death) and liver failure. Glaxo Wellcome, the company which markets the drug in this country, and the Medicines Control Agency believe that since the harmful effects and the risks cannot be predicted accurately, the drug would not be safe for some patients, particulary those with the type of diabetes known as type 2. Troglitazone is still available in the United States because the Food and Drug Administration (FDA) said that the benefits outweighed the risks - as long as patients receiving the drug are continuously monitored for signs of liver injury. The FDA has also suggested that a label should prominently display a warning of the drug's harmful side effects. G1axoWellcome has now withdrawn its application to market troglitazone across Europe (BMJ,1997; 315:1564). Copyright © 1997 What Doctors Don't Tell You (Volume 8, Issue 11)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next